TODAY: The Balancing Act Airs Informational IBD Segment

TODAY: The Balancing Act Airs Informational IBD Segment

The Balancing ActAn informational health segment on the management of inflammatory bowel disease (IBD) will be featured on the TV show “The Balancing Act,” today, Wednesday, April 8 at 11:30 am EDT/ 7:30 am PDT on Lifetime Television. The program will explore the use of prescription medical food product EnteraGam by patients who suffer from IBD, a series of conditions that affect 40 million patients in the United States alone.

The segment on IBD and diarrhea management and the influence of EnteraGam will be discussed by Board certified gastroenterologist and specialist in functional bowel disease, Christine Frissora, MD, as well as the medical scientist Victoria Jaison, PhD. The healthcare providers will also educate viewers on therapeutic options for these common gastrointestinal conditions, which cause abdominal pain and discomfort, as well as abnormal bowel habits.

The conversation will be focused on EnteraGam, which is prescribed to IBD patients to supplement the nutritional needs of their demanding clinical diet due to the disease. The use of EnteraGam, a protein product produced and commercialized by Entera Health, Inc., requires the supervision of a physician and needs to be included in a medical care plan.

In addition to IBD, irritable bowel syndrome with diarrhea (IBS-D), and HIV-associated enteropathy, EnteraGam may also be used under prescription by patients who suffer from limited or impaired ability to ingest, digest, absorb, or metabolize ordinary food or certain nutrients due to enteropathy for the management of intestinal complications.

Despite the fact that studies for the product revealed that it is well tolerated, adverse effects associated with it include mild nausea, constipation, stomach cramps, headache, and increased urination. In addition, it is also contraindicated in people with a hypersensitivity or allergy to beef and its effects in pregnant and nursing mothers have not been clinically assessed.

Key representatives of biotechnology company Entera Health were also invited last December to attend the Crohn’s & Colitis Foundation’s Clinical & Research Conference entitled, “Advances In Inflammatory Bowel Diseases” in Orlando, FLLarry Good of the State University of New York presented two posters, while Abigail Henderson from Cary, North Carolina, presented on Entera’s lead therapeutic candidate for IBD.